Results 141 to 150 of about 18,081 (213)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury. [PDF]

Kidney Med
Strimaitis BJ, Francis L, O'Sullivan ED.
europepmc   +1 more source

Decreasing Proprotein Convertase 5 Causes Hirschsprung's Disease by Disrupting Neural Crest Cell Migration. [PDF]

Cell Mol Gastroenterol Hepatol
Liu Z, Ma Z, Zuo X, Lan C, Chen Y, Liu Z, Zhong W, Chen J, Xie X, Xu X, Wu Q, Huang L, Zeng J, Zhong W, Xia H, Zhang Y.   +15 more
europepmc   +1 more source

The Proprotein Convertase BLI-4 Is Required for Axenic Dietary Restriction Mediated Longevity in Caenorhabditis elegans. [PDF]

Aging Cell
Wu P, Vandemeulebroucke L, Cai H, Braeckman BP.   +3 more
europepmc   +1 more source

Inhibition of proprotein convertase SKI-1 prevents blood vessel alteration after stroke. [PDF]

Nat Cardiovasc Res
Shabanzadeh AP, Ringuette D, Syonov M, Wu Q, Tassew NG, Mun EK, Meek A, Lively S, Suntharalingham SE, Mojica M, Olijnyk L, Qiang B, Foltz WD, Reed M, Moya I, Brown C, Feng J, Qin X, Akula PS, Wälchli T, Carlen PL, Alcaide-Leon P, Monnier PP.   +22 more
europepmc   +1 more source

Expression of pro- and anti-inflammatory cytokines during anti-proprotein convertase subtilisin/kexin type 9 therapy in patients with statin-resistant familial hypercholesterolemia [PDF]

Julieta D. Morales-Portano, Rafael Trujillo-Cortés, Bricia Roa-Martínez, Rebeca Pérez‐Cabeza de Vaca, Silvia García, Paul Mondragón‐Terán, Juan Antonio Suárez‐Cuenca   +6 more
openalex   +1 more source

Association between proprotein convertase subtilisin/kexin type 9 targeted therapies and the risk of arrhythmias: a meta-analysis of randomized controlled trials. [PDF]

Am J Prev Cardiol
Jaiswal V, Goyal A, Deb N, Shama N, Mittal V, Rajak K, Halder A, Khadka S, Kumar T, Ahmed R, Bytyçi I, Banach M, Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group.   +12 more
europepmc   +1 more source

Correction: Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review. [PDF]

Cureus
Rabih AM, Niaj A, Raman A, Uprety M, Calero MJ, Villanueva MRB, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Mohammed L.   +12 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study

, 2019
Cynthia Picard, Alexandre Poirier, Stéphanie A.H. Bélanger, Anne Labonté, Daniel Auld, Judes Poirier   +5 more
openalex   +2 more sources

Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. [PDF]

PeerJ
Li Z, Li X, Zhang Y, Qi J, Ji L, Li S, Gu M, Liu Y, Zhang Y, Mei Y, Wang M, Zhou J, Su M, Zhu L, Deng Q.   +14 more
europepmc   +1 more source

Alterations in the Expression of Proprotein Convertase Genes in Human Esophagus Squamous Cell Carcinomas. [PDF]

Acta Naturae
Komissarov AA, Zinovyeva MV, Sass AV, Vinogradova TV, Koshechkin SI, Demkin VV, Zborovskaya IB, Kostrov SV, Demidyuk IV.   +8 more
europepmc   +1 more source